Ireland

“Four or five major acquisitions over the last few years repositioned it, a 140-year-old company, from being a B-to-B company to B-to B-to-C company. That is a major enterprise strategy shift,” says CEO Patrick Lockwood-Taylor.

“In a very siloed organization made up of a jigsaw of different companies, no one was thinking enterprise first,” says Perrigo CEO Patrick Lockwood-Taylor. “The fundamentals of running operations, brand-building, innovation, they are now as they were.”

UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.

The Irish firm has raised a total of $60m to develop its antibody-oligonucleotide conjugate platform.

The Irish government has struck new in-principle agreements with the innovator and off-patent pharmaceutical sectors to help make the health care system more sustainable.

Generics Bulletin reviews global regulatory developments across the world.

Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

Ireland, which according to industry experts has an “outsized” voice in representing the pharmaceutical sector, is set to take over the presidency of the Council of the European Union next summer.

“We continue to grow the brand. It was slower than initially anticipated or forecasted in basis, but I'm pleased with how it's developing,” says CEO Patrick Lockwood-Taylor of Opill performance.

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

Ireland’s current voluntary system for disclosing pharmaceutical company payments to health care professionals and organizations is flawed and does not adequately deal with conflicts of interests, according to an Irish law maker.